- Prev close
- $89.17
- Day range
- $88.18 – $90.39
DXCM's +1.6% move looks benign: it came with the Nasdaq 100 up +0.6% and fits a stock that still has +15.5% revenue growth, +79.4% EPS growth, and margin expansion.
DXCM
DEXCOM INC
As of Sep 20, 2026
74/100
Looks healthyHealth ScoreMove driver
DXCM rose +1.6% while the S&P 500 slipped -0.1% and the Nasdaq 100 gained +0.6%, so the session was stronger than the market rather than a broad-index effect. With no sector peer moves provided, the cleanest read is stock-specific strength: the move sits against a backdrop of +15.5% revenue growth (TTM), +13.1% latest-quarter revenue growth, and +79.4% EPS growth (TTM), which supports an upward drift more than a macro explanation.
Volatility check
This looks like ordinary volatility for a higher-beta growth name, not a sign of deterioration. Beta is 1.45, so a 1.6% daily move is not out of character, and the operating picture remains strong at gross margin +64.3%, operating margin +22.9%, and net margin +20.1%. Valuation is still demanding at PE 33.7 and forward PE 26.1, while PEG 1.41 — the P/E divided by growth, so the price paid is about 1.41 times the growth rate — says growth is valued but not wildly detached from the fundamentals. The key point is that the move comes alongside intact growth and margins, not weakening business data.
Earnings preview
The next earnings date is not available this period, so I cannot pin the report to a calendar date. The latest facts point to a company that recently posted revenue of $1.31 billion with strong international growth and margin expansion, and the available growth profile is +13.1% in the latest quarter, +15.5% TTM revenue growth, and +79.4% TTM EPS growth. The market will be focused on whether that pace holds, whether margins stay near gross +64.3%, operating +22.9%, and net +20.1%, and whether international growth and glucose-monitoring adoption continue to offset valuation pressure from PE 33.7 and forward PE 26.1.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track DXCM with WhyIHold
Get a plain-English explanation the next time DEXCOM INC makes a big move — so you know whether it's benign or worth your attention.